This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hill-Rom (HRC) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $84.17 on Jul 14.
Avantor to Acquire VWR, Consolidation Promises Global Gains
by Zacks Equity Research
On Jul 14, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
by Zacks Equity Research
DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.
Abiomed (ABMD) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
With solid growth prospects Abiomed (ABMD) carries a Zacks Rank #1 (Strong Buy) which is an attractive pick at present.
Medtronic Enrolls First Patient Under STOP AF First Trial
by Zacks Equity Research
Medtronic (MDT) recently announced the first enrollment to its STOP AF First clinical trial.
Edwards Emerges Strong on FDA Nods, International Prospect
by Zacks Equity Research
On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).
Here's Why You Should Add ResMed to Your Portfolio Now
by Zacks Equity Research
California-based ResMed, Inc. (RMD) has been on a healthy growth trajectory of late.
CVS Health's MinuteClinic Joins EOHN for Workplace Healthcare
by Zacks Equity Research
MinuteClinic, the retail medical clinic of CVS Health Corporation (CVS), announced a tie-up with the Alere eScreen Occupational Health Network.
Express Scripts Rides High on Increased Generic Utilization
by Zacks Equity Research
On Jul 10, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation
by Zacks Equity Research
PAREXEL International Corporation (PRXL) was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.
RTI Surgical at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of RTI Surgical, Inc. (RTIX), based in Alachua, FL, scaled a new 52-week high of $6.00 on Jul 10, eventually closing a bit lower at $5.65.
Neogen Introduces Test for Listeria in Environmental Samples
by Zacks Equity Research
Neogen Corporation (NEOG) recently developed Listeria Right Now test system.
FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach
by Zacks Equity Research
Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.
Myriad Genetics to Grow with Study Successes, New Alliances
by Zacks Equity Research
On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).
Investors Look for Gains as Abbott Labs Set to Acquire Alere
by Zacks Equity Research
On majority of Alere shareholders' recent approval in favor of the merger with Abbott (ABT), the deal is now expected to close by the end of third-quarter 2017.
Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition
by Zacks Equity Research
On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).
ResMed Sees Potential in SDB Market, Eyes Global Growth
by Zacks Equity Research
On Jul 6, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Baxter and TAU Ink New Licensing Agreements through Ramot
by Zacks Equity Research
Baxter International (BAX) has recently teamed up with Tel Aviv University, Israel's largest research and teaching university (TAU), on two new licensing agreements through Ramot.
Mazor Expects Higher Q2 Revenues, Wins Mazor X Orders
by Zacks Equity Research
Mazor Robotics Ltd. (MZOR), recently announced that it expects to report second-quarter 2017 revenue of approximately $15.4 million compared with $8.3 million from the year-ago quarter.
Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for its INSPIRIS RESILIA aortic valve.
Will Walgreens Gain from Revised Rite Aid Agreement?
by Zacks Equity Research
The new agreement would enable Walgreens Boots Alliance (WBA) to buy nearly half of the Rite Aid business at a deal value, almost one-third of the original price.
Envision Healthcare Rallies on Infinity Healthcare Buyout
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) recently announced that Envision Physician Services has acquired Infinity Healthcare, a multi-specialty physician group practice.
Exactech (EXAC) Launches Application for Knee Replacement
by Zacks Equity Research
Gainesville, FL-based Exactech Inc. (EXAC) recently announced the launch of a new software application christened ExactechGPS TKA PLUS.
Civitas Solutions (CIVI) Acquires Country Life Care Center
by Zacks Equity Research
Civitas Solutions, Inc. (CIVI) recently announced the acquisition of Country Life Care Center, a rehabilitation and post-acute care facility located in Riverton, UT.
Patterson Companies Grapples with Multiple Issues: Dump Now?
by Zacks Equity Research
On Jul 4, we issued an updated research report on St. Paul, MN-based The Patterson Companies (PDCO).